parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in podocytes	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 17235

MARF1 in dopamine neurons, braak+0.42 (p 0.258) → +0.07 (p 0.857)receipt 17243
MARF1 in microglia, braak+0.37 (p 0.334) → +0.48 (p 0.194)receipt 17242

receipt 17243: MARF1 in dopamine neurons, braak

power: full sample +0.16 (p 0.521, n 18), 95% CI -0.33 to +0.58. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.23 (p 0.351, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.32 (p 0.194, n 18). could be the mix.
skeptic: leave-one-out range +0.06 to +0.26, sign flips 0; without severely affected donors +0.16 (p 0.521, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MARF1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 17242: MARF1 in microglia, braak

power: full sample +0.43 (p 0.079, n 18), 95% CI -0.05 to +0.74. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.43 (p 0.079, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.44 (p 0.066, n 18). could be the mix.
skeptic: leave-one-out range +0.34 to +0.60, sign flips 0; without severely affected donors +0.43 (p 0.079, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MARF1 in microglia.

case closed: nothing better to follow up.

loading the receipts